Amylyx Pharmaceuticals, Inc. (AMLX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
43 Thorndike Street
Cambridge, MA 02141
United States of America (the)
Phone
617 682 0917
Website
Sector
Healthcare
Industry
Biotechnology
Employees
123
First IPO Date
January 07, 2022
| Name | Title | Pay | Year Born |
| Justin Klee | Co-CEO & Director | 1.25M | 1991 |
| Joshua Cohen | Co-Founder, Co-CEO & Director | 1.25M | 1992 |
| Gina Mazzariello | Chief Legal Officer & General Counsel | 715,494 | 1972 |
| James Frates | Chief Financial Officer | 817,183 | 1967 |
| Camille L. Bedrosian | Chief Medical Officer | 1.01M | 1953 |
| Jamie Timmons | Head of Global Medical Strategy & Communications | 0 | N/A |
| Machelle Manuel | Vice President & Head of Global Medical Affairs | 0 | N/A |
| Dan Monahan | Chief Commercial Officer | 0 | N/A |
| Tom Holmes | Chief Technical Operations Officer | 0 | N/A |
| Linda A. Arsenault | Chief Human Resources Officer | 0 | N/A |
| Lindsey Allen | Head of Investor Relations & Communications | 0 | N/A |
| Tammy Sarnelli | Global Head of Regulatory Affairs | 0 | N/A |
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.